MD Anderson supports FDA proposal to prohibit menthol cigarettes
The University of Texas MD Anderson Cancer Center strongly encourages endorsement of the Food and Drug Administration (FDA) proposed rules to prohibit menthol cigarettes and flavored cigars.
The FDA banned the use of flavors in cigarettes in 2009, except for menthol. Today’s announcement represents a historic step closer to removing menthol cigarettes from the market. Once finalized, the product standards are...
Ribociclib added to endocrine therapy extends survival in postmenopausal patients with metastatic breast cancer
A study led by researchers from The University of Texas MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib...
High-fiber diet associated with improved progression-free survival and response to immunotherapy in melanoma patients
Patients with melanoma who reported eating more fiber-rich foods when they began immunotherapy treatment survived longer without cancer growth...
MD Anderson Research Highlights for December 15, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current discoveries include the functional role of collagen in bone development and disease, molecular determinants of lung cancer histology, a role for long noncoding RNAs in breast cancer metabolism, a new regulatory factor in hypoxia-induced...
Venetoclax combination therapies found effective against challenging subtypes of acute myeloid leukemia
ABSTRACTS 691, 371, 794
Combination therapies including venetoclax and another therapy have displayed promising results against subtypes...
Axi-cel CAR T cell therapy shows enhanced responses and continued benefit for high-risk lymphoma patients
ABSTRACTS 93, 739, 2
Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced...
MD Anderson Research Highlights: ASH 2021 Special Edition
ATLANTA ― The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into basic, translational and clinical...
MD Anderson Research Highlights for December 6, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
Belzutifan induced strong responses in patients with von Hippel-Lindau disease-associated kidney cancer
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center showed that treatment with belzutifan...
Antihistamines can influence immunotherapy response by enhancing T cell activation
New research from The University of Texas MD Anderson Cancer Center found that treatment with antihistamines, a commonly used allergy medication...
MD Anderson Research Highlights for November 17, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
MD Anderson Research Highlights: SITC 2021 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into basic, translational and clinical cancer research...
Collaboration on Data and Computational Sciences Announces Next Round of Projects to Advance Cancer Breakthroughs
The Oden Institute for Computational Engineering and Sciences (Oden Institute), The University of Texas MD Anderson Cancer Center ...
Combination immunotherapy improves survival for patients with asymptomatic melanoma brain metastases
Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival benefit for patients with...
MD Anderson Research Highlights for November 3, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
Serial radiation therapy is safe and effective as alternative treatment to systemic therapy for kidney cancer
In a new single-arm study, researchers at The University of Texas MD Anderson Cancer Center reported that radiation therapy as monotherapy...
MD Anderson Research Highlights: ASTRO 2021 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent studies in basic, translational and...
MD Anderson Research Highlights for October 20, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
Anil Sood, M.D., elected to the National Academy of Medicine
Anil Sood, M.D., professor of Gynecologic Oncology and Reproductive Medicine, has been elected to the National Academy of Medicine (NAM) for...
ATR inhibitor RP-3500 demonstrates safety and early clinical benefit
In a first-in-human, Phase I trial, researchers at The University of Texas MD Anderson Cancer Center discovered that ATR inhibitor RP-3500...
MD Anderson and Schrödinger announce strategic research collaboration to accelerate development of WEE1 program
The University of Texas MD Anderson Cancer Center and Schrödinger, Inc. today announced a two-year strategic research collaboration...
MD Anderson Research Highlights for October 6, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
Caroline Chung, M.D., named MD Anderson’s first Chief Data Officer
The University of Texas MD Anderson Cancer Center today named Caroline Chung, M.D., associate professor of Radiation Oncology and Diagnostic...
MD Anderson and the Rare Cancer Research Foundation launch collaboration to accelerate the development of treatments for rare cancers
The University of Texas MD Anderson Cancer Center and the Rare Cancer Research Foundation today announced the launch of a collaboration designed...
MD Anderson and Siemens Healthineers collaborating to enable consistent clinical implementation of quantitative MRI
The University of Texas MD Anderson Cancer Center and Siemens Healthineers today announced the collaborative development of a global education...
MD Anderson and BostonGene announce strategic alliance to advance personalized cancer diagnostics and treatments
The University of Texas MD Anderson Cancer Center and BostonGene Corporation today announced a strategic alliance to advance the development...
MD Anderson celebrates World Cancer Research Day, progress made to end cancer through research
The University of Texas MD Anderson Cancer Center is proud to support World Cancer Research Day, Sept. 24, and its efforts to promote cancer...
Active Living After Cancer program improves physical functioning of breast cancer survivors
Breast cancer survivors who participated in Active Living After Cancer, an evidence-based 12-week group program, markedly increased their...
MD Anderson Research Highlights for September 22, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
MD Anderson launches community-led Be Well™ Acres Homes initiative
With the launch of Be Well™ Acres Homes, The University of Texas MD Anderson Cancer Center unites more than 30 organizations, alongside community...
MD Anderson Research Highlights: ESMO 2021 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent studies in basic, translational and...
Link between inflammation and pancreatic cancer development uncovered
HOUSTON ― A new discovery from researchers at The University of Texas MD Anderson Cancer Center has clarified the long-established connection...
MD Anderson to pay tribute to legendary Emil J Freireich, M.D., in virtual celebration on Sept. 23
The University of Texas MD Anderson Cancer Center will celebrate the life of trailblazing oncologist Emil J Freireich, M.D., in a virtual...
Classifying EGFR mutations by structure and function offers better way to match non-small cell lung cancer patients to treatments
Researchers from The University of Texas MD Anderson Cancer Center have discovered that grouping epidermal growth factor receptor (EGFR) mutations...
Long-term benefit of SABR for operable early-stage NSCLC shown in new study
A new study from researchers at The University of Texas MD Anderson Cancer Center showed that stereotactic ablative radiotherapy (SABR) was...
MD Anderson and SNIPR BIOME collaborate to advance next-generation CRISPR microbiome therapeutics
The University of Texas MD Anderson Cancer Center and SNIPR BIOME today announced a strategic collaboration to advance new CRISPR-based microbiome...
MD Anderson Research Highlights for September 8, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
MD Anderson and Houston Dynamo FC team up to kick childhood cancer
HOUSTON ― The University of Texas MD Anderson Cancer Center is joining forces with Houston Dynamo FC to raise awareness of childhood cancer...
MD Anderson and Bellicum announce additional license agreement for use of CaspaCIDe® safety switch
The University of Texas MD Anderson Cancer Center and Bellicum Pharmaceuticals, Inc. today announced a global option and license agreement...
Omer Sultan joins MD Anderson as new Chief Financial Officer
The University of Texas MD Anderson Cancer Center today named Omer Sultan senior vice president and chief financial officer (CFO). With his...
MD Anderson Research Highlights for August 25, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
MD Anderson statement regarding third dose of COVID-19 vaccine for immunocompromised patients
A multidisciplinary group of oncology and infectious disease experts at The University of Texas MD Anderson Cancer Center have reviewed all...
CPRIT awards nearly $13 million in support of MD Anderson research
The University of Texas MD Anderson Cancer Center has been awarded $12.75 million from the Cancer Prevention and Research Institute of Texas...
MD Anderson Research Highlights for August 11, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
Researchers discover new factor in preventing phenylketonuria, offering new treatment strategy
Researchers at The University of Texas MD Anderson Cancer Center have discovered a critical new factor in regulating phenylalanine metabolism...
Statins may improve survival for triple-negative breast cancer patients
A study led by researchers from The University of Texas MD Anderson Cancer Center found a significant association between cholesterol-lowering...
MD Anderson Research Highlights for July 28, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
MD Anderson and Blueprint Medicines announce strategic collaboration to accelerate BLU-222 development
The University of Texas MD Anderson Cancer Center and Blueprint Medicines Corporation today announced a three-year strategic research collaboration...
MD Anderson again ranks No. 1 in cancer by U.S. News & World Report
The University of Texas MD Anderson Cancer Center again has been named No. 1 in cancer in the U.S. News & World Report’s 2021-2022 annual...
MD Anderson Research Highlights for July 14, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
Atezolizumab and bevacizumab show meaningful responses for malignant peritoneal mesothelioma patients
A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab...
Novel immunotherapy combination produces durable response in frontline metastatic melanoma
A Phase II cohort from the international PIVOT-02 study has shown the combination of interleukin-2 (IL-2) pathway agonist bempegaldesleukin...
MD Anderson and Hummingbird Bioscience announce strategic research collaboration to advance innovative immunotherapies
The University of Texas MD Anderson Cancer Center and Hummingbird Bioscience today announced the launch of a multi-year strategic research...
Study identifies gut microbes associated with toxicity to combined checkpoint inhibitors in melanoma patients
Researchers from The University of Texas MD Anderson Cancer Center found specific intestinal microbiota signatures correlate with high-grade...
MD Anderson Research Highlights for June 30, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published ...
Engineered NK cells can eliminate glioblastoma stem cells
Preclinical research from The University of Texas MD Anderson Cancer Center finds that although glioblastoma stem cells (GSCs) can be targeted...
MD Anderson Research Highlights for June 16, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
Combination targeted therapy provides durable remission for patients with chronic lymphocytic leukemia
A combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic...
Targeted therapy pralsetinib safely and effectively treats lung and thyroid cancers with RET alterations
Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers,...
Newly approved targeted therapy sotorasib prolongs survival in KRAS G12C-mutated lung cancer
ABSTRACT #9003
Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib...
Glioblastoma study discovers protective role of metabolic enzyme, revealing a novel therapeutic target
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel function for the metabolic enzyme medium-chain acyl-CoA...
MD Anderson researchers present new findings in targeted and combination therapies at 2021 ASCO Annual Meeting
Several Phase II clinical trials conducted by researchers from The University of Texas MD Anderson Cancer Center show promising results for...
MD Anderson and other top U.S. cancer centers call for urgent action to get cancer-preventing HPV vaccination back on track
The University of Texas MD Anderson Cancer Center has united with fellow National Cancer Institute (NCI)-Designated Cancer Centers and partner...
New AI-based tool can find rare cell populations in large single-cell datasets
Researchers at The University of Texas MD Anderson Cancer Center have developed a first-of-its-kind artificial intelligence (AI)-based tool...
CPRIT renews funding for MD Anderson training program focused on education and research
Today, the Cancer Prevention and Research Institute of Texas (CPRIT) awarded The University of Texas MD Anderson Cancer Center $4 million...
Combination therapy achieves high rates of response for patients with acute lymphoblastic leukemia
ABSTRACT #7001
A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed...
Metabolic inhibitor IACS-6274 shows early antitumor effects in underserved patients with advanced cancers
ABSTRACT #3001
The glutaminase (GLS1) inhibitor IACS-6274, discovered and developed by The University of Texas MD Anderson Cancer Center...
MD Anderson and Refuge Biotechnologies collaborate to advance next-generation cell therapies for treatment of solid tumors
The University of Texas MD Anderson Cancer Center and Refuge Biotechnologies, Inc. today announced a strategic collaboration to advance new...
NK cells with bispecific antibody show activity against lymphoma cells
Cytokine-activated natural killer (NK) cells derived from donated umbilical cord blood, combined with an investigational bispecific antibody...
Mitochondrial enzyme found to block cell death pathway points to new cancer treatment strategy
The mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) plays an important and previously unknown role in blocking a form of cell death...
MD Anderson and Broad Institute launch new translational research platform focused on rare cancers
The University of Texas MD Anderson Cancer Center and the Broad Institute of MIT and Harvard today announced the launch of a new translational...
Single-cell map of early stage lung cancer and normal lung sheds light on tumor development, new therapeutic targets
Researchers at The University of Texas MD Anderson Cancer Center have developed a first-of-its-kind spatial atlas of early-stage lung cancer...
Antiviral T cells safe and effective for treating debilitating complication common after stem cell transplants
A Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center found that BK virus (BKV)-specific T cells from healthy...
MD Anderson advances data collaboration through technology agreement with Syntropy
The University of Texas MD Anderson Cancer Center today announced efforts to advance its capabilities to seamlessly connect basic science,...
ASCO recognizes three MD Anderson faculty with highest honors
The American Society of Clinical Oncology (ASCO) today announced it will present three of its highest honors to faculty members from The University...
MD Anderson researcher Sharon Dent elected to American Academy of Arts and Sciences
Sharon Dent, Ph.D., professor of Epigenetics and Molecular Carcinogenesis, and director of the Virginia Harris Cockrell Cancer Research Center...
MD Anderson and Boehringer Ingelheim expand collaboration to advance lung cancer therapies
The University of Texas MD Anderson Cancer Center and Boehringer Ingelheim today announced the extension and expansion of their joint Virtual...
Researchers identify surface protein as a new osteosarcoma therapeutic target for antibody-drug conjugates
Abstract #LB008
A preclinical study led by researchers at The University of Texas MD Anderson Cancer Center shows an antibody-drug...
MD Anderson researchers highlight advances in clinical studies at the AACR Annual Meeting 2021
Early phase clinical trials conducted by researchers from The University of Texas MD Anderson Cancer Center show promising results for patients...
Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis
ABSTRACT #2417
Researchers at The University of Texas MD Anderson Cancer Center have discovered that mutant KRAS and p53, the most...
MD Anderson researchers recognized by AACR
Three researchers from The University of Texas MD Anderson Cancer Center have been honored by the American Association for Cancer Research...
MD Anderson and TriSalus Life Sciences announce strategic research collaboration to evaluate treatment of solid tumors
The University of Texas MD Anderson Cancer Center and TriSalus Life Sciences today announced a strategic research collaboration to evaluate...
Genetic diversity within tumors suggests continuous evolution
By analyzing tumors from more than 2,600 patients and from 38 cancer types, researchers from The University of Texas MD Anderson Cancer Center...
MD Anderson’s Guillermina Lozano elected to Fellows of the AACR Academy
Guillermina (Gigi) Lozano, Ph.D., chair of Genetics at The University of Texas MD Anderson Cancer Center, has been elected...
New sequencing approach finds triple-negative breast cancers continue accumulating genetic changes during tumor growth
Overcoming previous technical challenges with single-cell DNA (scDNA) sequencing, a group led by researchers at The University of Texas MD...
Study finds high tumor mutation burden predicts immunotherapy response in some, but not all, cancers
A high rate of genetic mutations within a tumor, known as high tumor mutation burden (TMB), was only useful for predicting clinical responses...
MD Anderson, Orionis launch Project Helios to advance new cancer medicines
The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery division and Orionis Biosciences today announced the launch of...
Collagen plays protective role during pancreatic cancer development
Contrary to long-held beliefs, Type I collagen produced by cancer-associated fibroblasts may not promote cancer development but instead plays...
Break Through Cancer launches collaborative model with MD Anderson, top U.S. research institutions in pursuit of cancer cures
Break Through Cancer today announced its formal launch as a public foundation designed to find new solutions to the most intractable challenges...
Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III...
MD Anderson and Mirati Therapeutics announce KRAS strategic research and development collaboration in solid tumors
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development...
MD Anderson celebrates World Cancer Day and the global initiative to end cancer
The University of Texas MD Anderson Cancer Center is proud to support World Cancer Day, Feb. 4, to honor the international effort to eliminate...
Legendary MD Anderson faculty member Dr. Emil J Freireich passes away at 93
Emil J Freireich, M.D., a trailblazing oncologist who developed groundbreaking therapies for childhood leukemia and came to be recognized...
MD Anderson launches new Strategy and expands core values
The University of Texas MD Anderson Cancer Center today launched a pivotal, multi-year Strategy aimed at making the greatest impact on humanity...
Study defines small-cell lung cancer subtypes and distinct therapeutic vulnerabilities for each type
Researchers from The University of Texas MD Anderson Cancer Center have developed the first comprehensive framework to classify small-cell...
Robin Roberts, Charles Barkley and TNT's Ernie Johnson Jr. team up to #EndCancer on Feb. 4
An all-star lineup of basketball greats, several of whom are courageous cancer survivors, will share their stories Feb. 4 at The University...
New computational tool reliably differentiates between cancer and normal cells from single-cell RNA-sequencing data
In an effort to address a major challenge when analyzing large single-cell RNA-sequencing datasets, researchers from The University of Texas...
MD Anderson and UroGen Pharma announce strategic research collaboration to advance investigational treatment for high-grade bladder cancer
The University of Texas MD Anderson Cancer Center and UroGen Pharma Ltd. today announced a strategic three-year collaboration agreement to...
Mediterranean diet may decrease risk of prostate cancer progression for men on active surveillance
In a study to examine a Mediterranean diet in relation to prostate cancer progression in men on active surveillance, researchers from The...
MD Anderson and Xencor enter strategic collaboration to develop novel T cell-engaging bispecific antibodies for potential treatment of patients with cancer
The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic research collaboration and commercialization...
Single-cell analysis of metastatic gastric cancer finds diverse tumor cell populations associated with patient outcomes
Researchers from The University of Texas MD Anderson Cancer Center who profiled more than 45,000 individual cells from patients with peritoneal...
Immunology study finds protein critical to T cell metabolism and anti-tumor immune response
Researchers at The University of Texas MD Anderson Cancer Center have discovered that a protein called NF-kappa B-inducing kinase (NIK) is...